Go Deep
Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -58,949 | -5.5 | 82.50 | 39.03 | 1,328.51 |
| Oct 2026 | -57,625 | -5.4 | 80.02 | 39.03 | 1,284.64 |
| Oct 2026 | -58,003 | -5.6 | 80.73 | 39.03 | 1,296.22 |
| Oct 2026 | -55,639 | -5.1 | 76.29 | 39.03 | 1,221.82 |
| Oct 2026 | -56,238 | -5.2 | 77.42 | 39.03 | 1,241.15 |
| Oct 2026 | -56,742 | -5.3 | 78.36 | 39.03 | 1,256.32 |
| Oct 2026 | -56,427 | -5.2 | 77.77 | 39.03 | 1,243.76 |
| Oct 2026 | -57,751 | -5.4 | 80.25 | 39.03 | 1,280.88 |
Syndax Pharmaceuticals, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 72,788,000.0 | 64,864,000.0 | 68,728,000.0 | 45,871,000.0 |
| Net Profit | -49,363,000.0 | -42,673,000.0 | -68,014,000.0 | -60,715,000.0 |
| EPS | -0.6 | -0.5 | -0.8 | -0.7 |
Syndax Pharmaceuticals, Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 172,352,000.0 | 23,680,000.0 | 0.0 | 0.0 | — |
| Net Profit | -285,422,000.0 | -318,758,000.0 | -209,360,000.0 | -149,338,000.0 | — |
| EPS | -3.3 | -3.7 | -3.0 | -2.5 | — |
Syndax Pharmaceuticals, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 529,706,000.0 | 724,816,000.0 | 612,880,000.0 | 497,236,000.0 | — |
| Total Liabilities | 465,076,000.0 | 436,692,000.0 | 58,684,000.0 | 29,787,000.0 | — |
| Total Equity | 64,630,000.0 | 288,124,000.0 | 554,196,000.0 | 467,449,000.0 | — |
Owes vs Owns
Syndax Pharmaceuticals, Inc. owed $0.98 for every $1 it owned in Jun 2026, up from $0.06 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.98× | 0.88× | 0.60× | 0.10× | 0.06× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Syndax Pharmaceuticals, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 78.1%Receivables 13.3%Inventory 6.2%Other assets 2.2%
How it's funded — Dec 2025
Long-term debt 64.9%Payables 3.1%Other liabilities 19.7%Shareholders' equity 12.2%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 413.7 | 582.9 | 577.6 | 484.4 |
| Receivables | 70.3 | 13.9 | 1.2 | 4.1 |
| Inventory | 32.8 | 0.4 | 0.0 | 0.0 |
| Fixed assets (tangible) | 1.5 | 2.0 | 1.5 | 1.1 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 119.5 | 29.8 | 5.5 |
| Other assets | 11.5 | 6.1 | 2.7 | 2.3 |
| Liabilities & equity | ||||
| Short-term debt | 0.5 | 12.1 | 1.0 | 0.4 |
| Long-term debt | 343.9 | 331.6 | 0.6 | 0.7 |
| Payables | 16.6 | 11.6 | 10.0 | 4.3 |
| Other liabilities | 104.1 | 81.4 | 47.1 | 24.3 |
| Shareholders' equity | 64.6 | 288.1 | 554.2 | 467.4 |
| Net tangible assets | 64.6 | 288.1 | 554.2 | 467.4 |
Syndax Pharmaceuticals, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -322,980,000.0 | -274,903,000.0 | -160,601,000.0 | -133,675,000.0 | — |
| Investing Activities | 290,036,000.0 | -219,775,000.0 | 117,609,000.0 | -186,188,000.0 | — |
| Financing Activities | 13,676,000.0 | 353,367,000.0 | 264,132,000.0 | 172,254,000.0 | — |